Use of thiazolidinediones and the risk of colorectal cancer in patients with diabetes: a nationwide, population-based, case-control study.
Use of thiazolidinediones and the risk of colorectal cancer in patients with diabetes: a nationwide, population-based, case-control study.
复制标题
在糖尿病患者中使用噻唑烷二酮和结直肠癌的风险：全国，基于人群的病例对照研究。
DOI：
10.2337/dc11-2197
复制
发表时间：
2013-02
期刊：
影响因子：
16.2
通讯作者：
Health Data Analysis in Taiwan Research Group
中科院分区：
文献类型：
--
作者：
Chen SW;Tsan YT;Chen JD;Hsieh HI;Lee CH;Lin HH;Wang JD;Chen PC;Health Data Analysis in Taiwan Research Group
临床前数据表明，过氧化物酶体增殖物激活受体γ（PPARγ）激动剂在结直肠癌中具有抑制作用。我们的目的是评估以噻唑烷二酮（TZD）为代表的合成PPARγ激动剂的使用与患结直肠癌风险之间的关系。我们使用台湾全民健康保险研究数据库进行了一项全国性的、以人群为基础的病例对照研究。病例受试者被定义为在2000年至2008年期间新诊断结直肠癌之前至少365天被诊断患有糖尿病的患者。我们随机选择糖尿病对照受试者作为每个病例的受试者，这些受试者在性别、年龄和糖尿病持续时间上相匹配。在24，496例合格病例受试者和对照受试者中，我们使用条件Logistic回归评估与使用TZD相关的结直肠癌风险。进行了一项额外的分析，以评估合并使用TZD和低剂量阿司匹林或非甾体抗炎药（NSAID）对结直肠癌风险的影响。与从未使用过TZD的患者相比，使用过TZD的患者发生结直肠癌的风险降低（校正比值比0.86 [95% CI 0.79-0.94]）。此外，还发现伴随使用TZD和低剂量阿司匹林或NSAID可降低结直肠癌风险。TZD的使用可能与糖尿病患者结直肠癌风险降低有关。需要进一步的研究来证实我们的发现。
Preclinical data suggest that peroxisome proliferator–activated receptor γ (PPARγ) agonists have antineoplastic effects in colorectal cancer. We aimed to assess the association between the use of synthetic PPARγ agonists, represented by thiazolidinediones (TZDs), and the risk of developing colorectal cancer. We conducted a nationwide, population-based, case-control study using the Taiwan National Health Insurance Research Database. Case subjects were defined as patients who were diagnosed with diabetes at least 365 days prior to a new diagnosis of colorectal cancer between 2000 and 2008. We randomly selected diabetic control subjects for each case subject, which were matched by sex, age, and the duration of diabetes. Among the 24,496 eligible case subjects and control subjects, we used conditional logistic regression to assess the risk of colorectal cancer in association with the use of TZDs. An additional analysis was conducted to assess the effects of concomitant use of TZDs and low-dose aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) on the risk of colorectal cancer. A decreased risk of colorectal cancer was observed in patients who had used TZDs compared with those who had never used TZDs (adjusted odds ratio 0.86 [95% CI 0.79–0.94]). Furthermore, the benefit of a decreased colorectal cancer risk was also found with concomitant use of TZDs and low-dose aspirin or NSAIDs. The use of TZDs may be associated with a decreased risk of colorectal cancer in patients with diabetes. Further studies are warranted to confirm our findings.
登录
查看更多内容
影响因子：
9.8
作者：
Ruder, Elizabeth H.;Laiyemo, Adeyinka O.;Graubard, Barry I.;Hollenbeck, Albert R.;Schatzkin, Arthur;Cross, Amanda J.
通讯作者：
Cross, Amanda J.
影响因子：
82.9
作者：
Sarraf, P;Mueller, E;Spiegelman, BM
通讯作者：
Spiegelman, BM
影响因子：
--
作者：
Smalley, W;Ray, WA;Griffin, MR
通讯作者：
Griffin, MR
影响因子：
64.8
作者：
Kersten, S;Desvergne, B;Wahli, W
通讯作者：
Wahli, W
影响因子：
16.2
作者：
Ferrara A;Lewis JD;Quesenberry CP Jr;Peng T;Strom BL;Van Den Eeden SK;Ehrlich SF;Habel LA
通讯作者：
Habel LA